Independent report · B2B Commerce / SME Lending

OfBusiness Pre-IPO Shares: Valuation vs Profit Risk

June 28, 2026 · By Anurag

OfBusiness company material

Independent report content

SECONDARYDEALNOTE · # 0 0 7

OfBusiness Pre-IPO Secondary B2B Commerce + SME Lending · Z47 $200M Stake Sale · Pre-IPO $5B current valuation IPO target $6–9B June 28, 2026

BUSINESS QUALITY AMBER PROFIT TRAJECTORY RED IPO PROXIMITY GREEN

SELLER SIGNAL RED VALUATION RISK AMBER

SECON DA RY TY P E Pre-IPO secondary — Z47 selling a partial stake (~$200M) ahead of OfBusiness's planned IPO. Z47 holds 10.8% ($540M at $5B). $200M sale = liquidating ~37% of its OfBusiness position. SELLERZ47 (formerly Matrix Partners India) — an original backer of OfBusiness.

Exiting pre-IPO to generate DPI for its first independent fund ($300–400M, currently raising). BUYERPROFILE Pre-IPO institutional buyers, secondary funds, large family offices. Given the $200M ticket: likely sovereign funds, PE secondaries, or a large institution. Not retail accessible.

CURRENT VA LUAT ION $5B (Tracxn, Inshorts Jun 2026). Total raised $1.14B. Z47 stake 10.8% = $540M paper value at $5B; selling $200M = partial liquidity event. IPO TA RGET $6–9B. Five banks mandated: Axis Capital, Morgan Stanley, JPMorgan, Citigroup, BofA (Nov 2024). Size $750M–$1B (fresh issue $200M + OFS).

Target: FY26 (by Mar 2027). FY 2 5 FINANCIALS Operating revenue ₹19,296 Cr (+19% YoY) | PAT ₹222 Cr (−67% YoY from ₹669 Cr) | Oxyzo (NBFC): ₹1,207 Cr revenue, ₹339 Cr PAT (+16.5%) | 17,000 employees.

RUPEIA OFBUSINESS PRE-IPO SECONDARY SECONDARY DEAL NOTE #007

W H AT ITDOES Two businesses in one entity: (1) B2B commerce — procurement

marketplace for industrial raw materials (steel, chemicals, polymers) for

SME manufacturers; (2) Oxyzo — NBFC providing working-capital credit to the same SMEs. The flywheel reinforces both.

THERUPEIANUMBER

The percentage by which OfBusiness's PAT collapsed in FY25 — from ₹669 Cr (FY24) to ₹222 Cr (FY25) — even as revenue grew 19%. That is ₹447 Cr of profit destruction in a single year. Z47 is selling $200M of stock in the same quarter this number became public. The buyer must understand why profit fell 67% before committing.

THEG AT INGQUESTION

OfBusiness's PAT fell 67% in FY25 — from ₹669 Cr to ₹222 Cr — while revenue grew 19%. This is not a minor miss; it is a fundamental economics question. Before buying Z47's $200M stake in a company targeting a $6–9B IPO, a buyer must understand: (1) WHY did profit collapse? (2) Is it one-time (credit provisioning, ESOP, restructuring) or structural (margin compression)? (3) Does Oxyzo's NBFC book carry NPA risk that has not yet shown in the P&L? The IPO banks were mandated in November 2024, before the FY25 PAT was available — their continued mandate after diligence is a positive signal, but the buyer must do the same work.

RUPEIA INVESTMENT INTELLIGENCE | JUNE 28, 2026 | SECONDARY DEAL NOTE #007 | PREPARED INDEPENDENTLY

0A CLAIM REGISTER — EVIDENCE GRADING

A = Statutory/regulatory | B = MCA-adjacent / company disclosure | C = Independent press / database | D = Company statement | E = No evidence or conflict

CLAIM SOURCE GRADE RUPEIA ASSESSMENT

FY25 Revenue ₹19,296 Cr (+19% YoY) Inc42 IPO Tracker 2026; MCA- adjacent B HIGH CONFIDENCE on the figure. Consistent with FY24 ₹15,342 Cr. BUT see revenue-basis conflict (Section 3) — likely GMV, not net revenue.

FY25 PAT ₹222 Cr (−67% from ₹669 Cr) Inc42 IPO Tracker 2026; Inc42 FY24 data B HIGH CONFIDENCE. The single most important financial signal in this note.

Z47 holds 10.8% stake in OfBusiness Inshorts via Moneycontrol Jun C PROBABLE. Consistent with Tracxn cap table (funds hold 67.52% total). Stake size plausible.

Z47 plans $200M secondary sale Moneycontrol via Inshorts Jun C PROBABLE — recent report. Transaction not confirmed closed; Z47 and OfBusiness have not publicly confirmed.

$5B current valuation Tracxn Jun 2026; Inshorts Jun B HIGH CONFIDENCE. Consistent across sources; implied by founder net worth ₹11,400 Cr (27.3% at $5B ≈ ₹11,265 Cr). IPO target $6–9B Inc42 IPO Tracker 2026; press citing CFO Bhavesh Keswani B HIGH CONFIDENCE. CFO-stated. Five banks mandated. $750M– $1B IPO size stated.

RUPEIA OFBUSINESS PRE-IPO SECONDARY SECONDARY DEAL NOTE #007

CLAIM SOURCE GRADE RUPEIA ASSESSMENT

Oxyzo FY25 revenue ₹1,207 Cr, PAT ₹339 Cr The Head and Tale (Entrackr data) May 2025 B HIGH CONFIDENCE. Entrackr MCA-derived. Oxyzo is a separately incorporated NBFC — audited financials available.

17,000 employees PitchBook Jun 2026 B HIGH CONFIDENCE — PitchBook profile. Five banks mandated Nov 2024 Inc42 (Nov 2024); multiple press A VERIFIED. Axis Capital, Morgan Stanley, JPMorgan, Citi, BofA publicly confirmed.

1 COMPANY OVERVIEW — THE COMMERCE + LENDING

FLYWHEEL

OfBusiness is misunderstood by most investors as a marketplace. It is more accurately a vertical NBFC that uses a B2B commerce platform as its credit origination and data engine. ENTI TY OFB Tech Limited. HQ: Gurugram, Haryana. Founded 2015. FOUNDERS Asish Mohapatra (CEO), Ruchi Kalra (COO & CFO of Oxyzo), Bhuvan Gupta, Chandranshu Sinha, Nitin Jain, Srinath Ramakkrushnan, Vasant Sridhar. A 7- founder team — the largest among India's top unicorns. Founders hold 27.3% (₹11,400 Cr at $5B).

B 2 BCOMMERCEARM Procurement marketplace for industrial raw materials: steel, chemicals, polymers, agri inputs, electronics. SME manufacturers buy; OfBusiness sources from large manufacturers/distributors. Transaction-based revenue; majority of the ₹19,296 Cr.

OXY ZO ( NBFCARM ) Working-capital credit to the same SMEs, backed by purchase-order + invoice data from the commerce arm. FY25: ₹1,207 Cr revenue, ₹339 Cr PAT. AUM likely ₹10,000–15,000 Cr (not publicly disclosed). THEF LYW HEEL SME buys steel on the platform → Oxyzo extends 30–90 day credit against the PO → OfBusiness captures repayment behaviour → Oxyzo has better credit data than any bank → risk-adjusted lending at superior margins → more SMEs join for credit access.

CAP TA BLE Funds 67.52% | Founders 27.30% | ESOP 3.89%. Total raised $1.14B. Investors: SoftBank, Tiger Global, Norwest, Alpha Wave Global, Marshall Wace, Z47. 8 institutional investors. COMPETITION Industrybuying, Moglix (B2B procurement); Lendingkart, Aye Finance, NBFCs (credit). The combination of commerce + credit is OfBusiness's differentiator — no direct competitor operates both at this scale.

RUPEIA OFBUSINESS PRE-IPO SECONDARY SECONDARY DEAL NOTE #007

2 THE $200M SECONDARY — WHY Z47 IS SELLING NOW

RUPEIAINTERPRE TAT ION — NOTS TAT EDBYZ 4 7

The seller-motivation analysis above is Rupeia's independent assessment based on public data and observed patterns in India PE secondary markets. Z47 has not stated these reasons publicly. Informed secondary buyers should independently verify Z47's stated rationale (fund lifecycle, LP request, etc.) before assuming this interpretation is complete.

3 FINANCIAL ANALYSIS — THE 67% PAT COLLAPSE

METRIC (₹

CR) FY23

(EST.) FY24 FY25 YOY RUPEIA FLAG

Operating

Revenue ~15,000 15,342* 19,296 +19% CONFLICT — *FY24 per another source is ₹1,906 Cr (commerce arm only). ₹15,342 Cr appears to be GMV. Verify with MCA. PAT ~463 669 222 −67% CRITICAL. Consistent across all sources.

Oxyzo Revenue ~600 903 1,207 +33.7% Strong NBFC growth. Oxyzo PAT ~200 291 339 +16.5% NBFC profitable and growing. Employees — ~14,000 17,000 +21% Significant headcount add = cost pressure. DPI over TVPI: Z47 is raising its first independent fund ($300–400M). LPs evaluate new funds on DPI — distributed cash, not paper marks. Razorpay ($7.5B mark), OfBusiness ($5B mark), Ola Electric (listed) = large paper portfolio. Converting to cash improves the DPI story before close.

– IPO timing risk: The OfBusiness IPO is targeted "by FY26" (Mar 2027) but not certain. If it slips to FY27, Z47's LPs wait another 18 months. A pre-IPO secondary locks in the exit at $5B rather than betting on a volatile IPO market.

– PAT-compression signal (Rupeia interpretation): Z47 has seen OfBusiness's FY25 internals — including the 67% PAT decline. Selling $200M now, while banks are still mandated and before FY25 results are widely analysed, is consistent with an informed seller exiting ahead of a difficult earnings narrative at IPO.

– Concentration: Z47 holds 10.8% = $540M at $5B — enormous concentration for a ~$1.5B AUM fund. Selling $200M reduces concentration from ~36% of AUM to ~23% — prudent risk management. –

RUPEIA OFBUSINESS PRE-IPO SECONDARY SECONDARY DEAL NOTE #007

REVENUE - FIGURECONFLICT — RESO LV EBEFOREINVESTING

Inc42 states FY25 revenue ₹19,296 Cr and FY24 revenue ₹1,906 Cr. Both cannot be correct — a 10x jump in one year is impossible for an established B2B marketplace. Likely: one figure is GMV (total value of goods transacted) and the other is Net Revenue (take rate / fee income). OfBusiness's marketplace earns 1–3% on commodity procurement — a ₹19,296 Cr GMV would generate ~₹200–600 Cr in net revenue, not ₹19,296 Cr. Rupeia cannot confirm the correct basis without a direct MCA filing. The PAT figures (FY24 ₹669 Cr, FY25 ₹222 Cr) are consistent across sources and likely correct. Verify the revenue basis (GMV vs net) from MCA before committing capital.

What may explain the 67% PAT decline

4 IPO SCENARIO ANALYSIS — WHAT THE BUYER IS PRICING

SCENARIO

IPO

VALUATION

EV/NET-REVENUE

(ASSUME NET ~₹600–

800 CR) EV/PAT (₹222 CR FY25) SECONDARY AT $5B

BEAR — IPO at current valuation $5B 6–8x ~140x PE Flat. Secondary at $5B = IPO price = no upside at listing.

BASE — IPO at $6– 7B $6–7B 8–10x 180–210x PE (expensive — requires FY26 PAT recovery)

20–40% upside at IPO. Requires PAT recovery to ₹500+ Cr in FY26. BULL — IPO at $8– 9B $8–9B 12–14x 360–405x PE (stretched) 60–80% upside. Requires PAT recovery + re-rating to a premium India B2B multiple.

Credit provisioning at Oxyzo: As the SME lending book scaled, NBFC rules require higher provisioning against NPA/stressed assets. A change in provisioning norms or an NPA increase reduces PAT without reducing revenue. – Commerce margin compression: Commodity procurement (steel, chemicals) is thin-margin. Global steel prices fell in FY25 — absolute margin per transaction fell even as volume grew, against a fixed cost base.

– Headcount expansion: 17,000 vs ~14,000 employees = ~3,000 new hires at ₹6–8 lakh/year = ₹180–240 Cr additional annual salary cost in FY25. – ESOP expense: Pre-IPO companies typically accelerate ESOP vesting and grant new ESOPs. Non-cash ESOP expense hits P&L without cash outflow.

–

RUPEIA OFBUSINESS PRE-IPO SECONDARY SECONDARY DEAL NOTE #007

WHYTHEP AT - RECOVERYQUESTIONISEVERYTHING

The $6–9B IPO target requires public-market investors to believe FY25 PAT of ₹222 Cr was anomalous — and that FY26/27 PAT returns to ₹500+ Cr. If recovery is confirmed in H1 FY26 management accounts (which the IPO banks will have), the secondary at $5B is attractive. If FY26 is also depressed — more Oxyzo NPA provisioning, continued commodity-margin compression, or further headcount cost — the IPO will face severe public scrutiny. Z47 selling $200M in June 2026, before FY26 H1 results are available, is the timing signal secondary buyers must process.

5 RISK MATRIX

RISK DETAIL MITIGANT RESIDUAL

67% PAT collapse in FY25 ₹669 Cr → ₹222 Cr with only 19% revenue growth. Cause unconfirmed from public sources.

Verify from MCA filing + management accounts. IPO-banker diligence is a proxy validator. HIGH until the cause is confirmed. Do not commit without this answer.

Oxyzo NPA risk NBFC lending to SMEs in commodity

sectors (steel, chemicals) during a weak

manufacturing cycle. NPA can spike in downturns. Oxyzo FY25 PAT ₹339 Cr (+16.5%) suggests the book is performing. But NPA can be a lagging indicator.

MEDIUM — profitable but provisioning could compress future PAT. Revenue-figure ambiguity ₹19,296 Cr vs ₹1,906 Cr FY24 — likely GMV vs net revenue. True net revenue may be ₹600–800 Cr = very different

valuation.

Verify via direct MCA filing (Tofler/TheKredible) before any capital commitment. HIGH until resolved —

valuation can't be

calculated without the correct basis. GMV take-rate compression B2B commodity marketplace operates on 1–3% margins. If commodity inflation subsides, absolute margin per

transaction falls.

Diversification into higher-margin Oxyzo credit reduces commodity exposure. MEDIUM — structural for a commodity marketplace.

IPO market timing "Targeted FY26" (by Mar 2027). Worse

market conditions (INR depreciation,

global risk-off) could slip it to FY27. Five banks mandated; IPO prep since 2024. Institutional readiness is high. MEDIUM — market- dependent.

Seller signal (Z47 exit) Z47 is exiting $200M pre-IPO with full access to management accounts, FY25 internals, and Oxyzo NPA data.

May be selling for fund lifecycle / DPI reasons unrelated to fundamentals. Cannot confirm without a Z47 statement. HIGH — weigh as the most important signal in this

transaction.

6 INVESTOR COMFORT CHECKS

CHECK WHAT TO VERIFY

Revenue basis Before anything else: confirm whether ₹19,296 Cr is GMV or Net Revenue. Download the MCA filing (Tofler / TheKredible). The valuation multiple is completely different depending on the answer. PAT-recovery evidence Ask Z47 or the company: what does H1 FY26 PAT look like? Recovery to a ₹350+ Cr run-rate supports the IPO story; continued depression means the 67% decline is structural.

Oxyzo NPA

disclosure

Request Oxyzo Gross/Net NPA as of March 2026. NBFC data above ₹100 Cr exposure is available via RBI CRILC. Cross-check before sizing exposure.

RUPEIA OFBUSINESS PRE-IPO SECONDARY SECONDARY DEAL NOTE #007

CHECK WHAT TO VERIFY

Z47 rationale Ask directly why Z47 is selling now. "Fund-life mandate" or "LP request" is verifiable and less concerning; a vague answer ("portfolio management") should be treated as a seller signal. IPO lock-in SEBI 6-month lock-in from acquisition date for AIF/VC secondary buyers. Buy Jun 2026 + IPO Oct 2026 → locked until ~Apr 2027. Size accordingly.

Block deal terms At a $200M ticket, this is likely a structured block with co-investment rights, ROFR, and information rights. Negotiate a board-observer seat or enhanced MIS as part of the secondary — you have leverage at this size.

7 SECONDARY DEAL VERDICT

THERUPEIAANSWER

OfBusiness is a genuinely unique business — the B2B commerce + NBFC flywheel has no exact Indian peer. The $5B valuation is not unreasonable for the model IF the FY25 PAT collapse was one-time. The Z47 $200M secondary is the most important signal: Z47 has full information access and is choosing to sell pre-IPO. The path to buying this confidently: (1) get the MCA FY25 filing — confirm revenue basis and PAT cause; (2) get H1 FY26 management accounts — confirm PAT recovery; (3) get Oxyzo NPA data. If all three confirm FY25 PAT was anomalous and recovery is underway, OfBusiness at $5B with a $6–9B IPO target is a 20–80% upside opportunity over a 12–18 month hold. Without those three, you are buying Z47's exit with worse information than the seller.

8 SOURCE LOG

REF SOURCE DATE KEY DATA

[1] Inc42 — Indian Startup IPO Tracker 2026 Jun FY25 revenue ₹19,296 Cr (+19%); FY24 ₹15,342 Cr; PAT FY25 ₹222 Cr (−67%); PAT FY24 ₹669 Cr; five banks mandated; IPO $750M–$1B.

[2] Inshorts via Moneycontrol Jun Z47 plans $200M secondary; holds 10.8% stake; valuation $5B. [3] Tracxn — OfBusiness shareholding Jun

Funds 67.52%, Founders 27.30%, ESOP 3.89%. Founder net worth ₹11,400 Cr.

Valuation $5B.

[4] The Head and Tale (Entrackr data) May Oxyzo FY25: revenue ₹1,207 Cr (+33.7%), PAT ₹339 Cr (+16.5%), finance cost ₹439 Cr, total expenses ₹755 Cr.

[5] PitchBook — OfBusiness profile Jun Founded 2015. Gurugram. 17,000 employees. $1.14B raised. Investors: SoftBank, Tiger Global, Norwest, Alpha Wave, Marshall Wace.

[6] Inc42 — Z47 secondary sale (original) Oct Z47 exploring $150–180M multi-company secondary incl. OfBusiness, Razorpay, Ola, Dailyhunt.

The Standard This is a secondary deal note prepared without access to the company data room. Every figure is independently sourced; where a figure conflicts (the revenue basis) or is unconfirmed (the $200M

transaction), it is labelled as such. OfBusiness is a unique commerce + NBFC flywheel, but the 67%

RUPEIA OFBUSINESS PRE-IPO SECONDARY SECONDARY DEAL NOTE #007

FY25 PAT collapse and the informed-seller signal from Z47 are the two facts that govern this

transaction. Resolve revenue basis, PAT-recovery evidence, and Oxyzo NPA before committing —

otherwise you are buying the seller's exit with worse information than the seller.

DISCLAIMER

This document is published strictly for informational, educational, and academic record-keeping purposes only. The publisher of this document is not a SEBI Registered Investment Adviser (RIA), nor a SEBI Registered Research Analyst (RA). This report does not constitute personal investment advice, an independent research report, a financial recommendation, or an offer or solicitation to buy, sell, or subscribe to any securities. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.

RUPEIA | SECONDARYDEALNOTE # 0 0 7 | OFBUSINESSZ 4 7 PRE - IPOSECONDARY | JUNE 2 8 , 2 0 2 6

RUPEIA OFBUSINESS PRE-IPO SECONDARY SECONDARY DEAL NOTE #007